axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

Gilead acquired the rights to Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for lymphoma in that deal – however, the drug continues to fall short of analyst expectations, bringing in $264m

Latest news

GSK forms cell therapy R&D pact with star-studded biotech

Working with Lyell, GSK aims to develop new technologies that improve cell therapies, notably by expanding their use beyond the blood cancers targeted by Gilead Sciences’ Yescarta(axicabtagene ciloleucel) and Novartis’
Gilead strikes $5.1bn deal to bolster ties with Galapagos

CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to build sales, bringing in $264m last year.
Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

and Gilead’s Yescarta (axicabtagene ciloleucel).
Gilead unveils plan to separate Kite cell therapy unit

The announcement, which was announced internally in March, comes as the company’s first CAR-T therapy Yescarta (axicabtagene ciloleucel) for lymphoma continues to show somewhat sluggish growth, with first quarter

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).